Page 33 - Aet News Today

Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.

By leveraging analytics to optimize the patient experience in clinical trials, patient attrition will decrease, improving clinical outcomes and research goals.

Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.

And creativity. this is called micro—dosing. i and creativity. this is called micro-dosing.— and creativity. this is called micro-dosina. ., , micro-dosing. i would sometimes take it a few _ micro-dosing. i would sometimes take it a few days _ micro-dosing. i would sometimes take it a few days in _ micro-dosing. i would sometimes take it a few days in a _ micro-dosing. i would sometimes take it a few days in a row - micro-dosing. i would sometimes take it a few days in a row and - take it a ...

The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside.

Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned. The research comes as concerns about PE-owned hospitals are intensifying — from leaders both within and outside of the healthcare industry.

A recent Oliver Wyman report laid out five Affordable Care Act trends to watch, including the rise of ICHRAs and the need for a "seamless member experience."

Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy. The deal builds on a relationship the companies started in 2022.

Biomarkers, electronic health records (EHR), genomic data, imaging data, labs, social media, wearable sensors, and more provide enormous new sources of RWD that can aid in new discoveries for the quality, efficacy, and safety of new drug therapies.

Expanding access to the existing mental care system alone won’t solve problems if the mechanisms for providing care are inefficient and ineffective. Access must come hand-in-hand with quality of care - which is where measurement-based care (MBC) comes into play.